Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
Vitamin D for COVID-19: real-time meta analysis of 101 treatment and 139 sufficiency studies
Covid Analysis (Preprint) (meta analysis)
26 Nov 2022    Source   PDF   Share   Tweet
• Statistically significant improvements are seen in treatment studies for mortality, ICU admission, hospitalization, and cases.
50 studies from 47 independent teams in 20 different countries show statistically significant improvements in isolation (36 for the most serious outcome).
• Random effects meta-analysis with pooled effects using the most serious outcome reported shows 65% [43‑79%] and 36% [30‑42%] improvement for early treatment and for all studies. Results are similar after restriction to 94 peer-reviewed studies: 62% [39‑76%] and 36% [30‑42%], and for the 59 mortality results: 68% [39‑84%] and 37% [28‑44%].
• Acute treatment (early 65% [43‑79%], late 47% [34‑58%]) shows greater efficacy than chronic prophylaxis (29% [21‑36%]).
• Late stage treatment with calcifediol/calcitriol shows greater improvement compared to cholecalciferol: 73% [57‑83%] vs. 42% [28‑53%].
• Sufficiency studies show a strong association between vitamin D sufficiency and outcomes. Meta analysis of the 139 studies using the most serious outcome reported shows 54% [49‑58%] improvement.
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 13% of vitamin D studies show zero events with treatment. The quality of non-prescription supplements can vary widely [Crawford, Crighton].
• All data to reproduce this paper and the sources are in the appendix. Other meta analyses for vitamin D treatment studies can be found in [D’Ecclesiis, Hosseini, Nikniaz, Shah, Tentolouris, Varikasuvu], showing significant improvements for cases, severity, mortality, mechanical ventilation, and ICU admission.
ImprovementStudies AuthorsPatients
Treatment RCTs 36% [17‑50%] 24 284 41,634
Treatment studies 36% [30‑42%] 101 1,013 181,970
Cholecalciferol treatment 35% [28‑41%] 91 891 173,493
Calcifediol/calcitriol treatment 52% [26‑69%] 10 122 8,477
Treatment mortality 37% [28‑44%] 59 552 61,928
Sufficiency studies 54% [49‑58%] 139 1,219 166,860
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit